Ir a las Transacciones
Salud

Olyos Group has acquired a controlling stake in NewScience

Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.

Olyos, headquartered in France, has been controlled since 2023 by European private equity firm Motion Equity Partners. With over 75 years of history, Olyos is an international nutrition and health platform, generating US$150 million (€130 million) in annual revenues. Olyos’ strategy is based on a combination of organic and inorganic growth across its brands, supported by a scientific and pharmaceutical-driven approach. To date, the group has completed seven strategic acquisitions to expand its geographic footprint.

Founded over 15 years ago by Juan Pablo Salas, NewScience is a well-established company in the nutritional supplements market, with a strong presence across categories such as omega-3, probiotics, specialized magnesium, collagen, vitamins and minerals. The company is the market leader in omega-3 supplements. NewScience operates a fully integrated, asset-light business model, outsourcing manufacturing, packaging and quality control, while focusing on R&D, top-tier suppliers and a strong commercial strategy. This approach has enabled the company to establish a presence in more than 1,700 points of sale, as well as digital channels. NewScience has nationwide coverage in Chile, operations in Ecuador and international expansion plans currently underway.

Oaklins’ team in Chile acted as the exclusive buy-side financial advisor to Olyos in the acquisition of a controlling stake in NewScience S.A. It provided strategic and financial advice throughout the transaction, including valuation analysis, transaction structuring and negotiations with the sellers. The Oaklins French team supported the early stages of the transaction, including the introduction that led to the mandate and the initial connection with Olyos.

Partes

Contáctese con el equipo de la transacción

Agustin Achondo

Director
Santiago, Chile
Oaklins LarrainVial

Antoine Lemaire

Socio
Paris, Francia
Oaklins France

Nicole Leigh

Analista
Santiago, Chile
Oaklins LarrainVial

Inés Pfingsthorn

Analista
Santiago, Chile
Oaklins LarrainVial

Transacciones relacionadas

EuroHospital Varna has been acquired by Intermedica Group
Salud

EuroHospital Varna has been acquired by Intermedica Group

EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.

Aprenda más
MEDIK Hospital Design Group has been acquired by STERIS
Servicios de Construcción e Ingeniería | Salud

MEDIK Hospital Design Group has been acquired by STERIS

The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.

Aprenda más
bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Salud

bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.

Aprenda más